



CALIFORNIA NEUROLOGY SOCIETY

“Neuroimmunology & Beyond II”

March 20 - March 22, 2026

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of CME Consultants and California Neurology Society. CME Consultants is accredited by the ACCME to provide continuing medical education for physicians.

CME Consultants designates this live activity for a maximum of 17.75 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All of the content certified by CME Consultants has been peer reviewed for content validation purposes and all of the relevant financial relationships listed below have been mitigated.

Commercial Support Statement: There is no commercial support for this activity.

Disclosure Statements

Planner Name	Financial Relationship(s)	Company	Relevant?	Mitigation Strategy
CME CONSULTANTS’ REVIEWERS				
Harold D. Damuth, Jr., MD	None	N/A	N/A	N/A
Lester Holstein, MD	None	N/A	N/A	N/A
Jerry L. Manoukian, MD	None	N/A	N/A	N/A
Michael J. Marchiano, MD	None	N/A	N/A	N/A
CME CONSULTANTS’ STAFF				
Lydia Barella-Bryant	None	N/A	N/A	N/A
Priscilla Graham	None	N/A	N/A	N/A
Nancy Williams	None	N/A	N/A	N/A
CNS PLANNERS				
Virginia (Ginnie) Ho	None	N/A	N/A	N/A
Stella B. Legarda, MD	None	N/A	N/A	N/A
Johanna Rosenthal, MD	None	N/A	N/A	N/A
George Sarka, MD, DrPH, MPH	None	N/A	N/A	N/A
Vaishnavi Vaidyanathan, MD	None	N/A	N/A	N/A
Robert Weinmann MD	None	N/A	N/A	N/A
Robyn G. Young, MD	None	N/A	N/A	N/A

Planner Name	Financial Relationship(s)	Company	Relevant?	Mitigation Strategy
FACULTY				
Rumyar V. Ardakani, MD	None	N/A	N/A	N/A
Regina Berkovich MD, Ph.D	Consultant, Advisory Board Member, Speaker, Research Grant Recipient	Alexion Pharmaceutical; Amgen; ANI Pharmaceuticals; Biogen; Bristol-Myers Squibb Company; EMD Serono; Genetech; Par Health (Mallinckrodt); Novartis; Sanofi	Yes	*Peer review
Thomas C. Cesario, MD	None	N/A	N/A	N/A
Adrien Dupanloup, DVM, DACVIM (Neurology)	None	N/A	N/A	N/A
Steve J. Holtz, MD (LEDGE)	None	N/A	N/A	N/A
David King-Stevens, MD, FAES	Speaker	Neurelis; UCB Pharma	Yes	*Peer review
	Speaker	SK bioscience	No	N/A
Jeffrey Klingman, MD	None	N/A	N/A	N/A
Stella B. Legarda, MD (LEDGE)	None	N/A	N/A	N/A
Avindra Nath, MD	None	N/A	N/A	N/A
John Pluinage, MD, PhD	None	N/A	N/A	N/A
Paula Ravin, MD	Sub-Investigator	Ionis Pharmaceuticals; Quince Therapeutics; Yoda Therapeutics	Yes	*Peer review
Rodrigo Rodriguez, Jr., MD	None	N/A	N/A	N/A
Johanna Rosenthal, MD (LEDGE)	None	N/A	N/A	N/A
George Sarka, MD, DrPH, FAAN, FACR, FACP	None	N/A	N/A	N/A
Pascal Sati, PhD	Consultant	Sanofi	Yes	*Peer review
	Research Grant	Biogen		
Laura E. Saucier, MD, MSc	None	N/A	N/A	N/A
William Shankle, MD	None	N/A	N/A	N/A

*Presentation materials have been peer reviewed and found to be fair, balanced, evidence-based, and free from commercial bias.

Planner Name	Financial Relationship(s)	Company	Relevant?	Mitigation Strategy
Perry B. Shieh, MD, PhD	Consultant, Contracted Research, Speaker	Alexion (AstraZeneca); Biogen; Genentech; Novartis	Yes	*Peer review
	Consultant, Contracted Research	Dyne Therapeutics; Sarepta Therapeutics; Solid Biosciences		
	Contracted Research	Abcuro; AMO Pharma; Arcellx; Astellas; Arthex; Avidity Biosciences; Edgewise Therapeutics; EpiCrispr Bio; NMD Pharma; Pfizer; PTC Therapeutics		
	Consultant, Speaker	UCB Pharma		
	Speaker	Amgen; Catalyst Pharmaceuticals; CSL Behring; Grifols		
Jonathan D. Snider, MD	None	N/A	N/A	N/A
Vaishnavi Vaidyanathan, MD	None	N/A	N/A	N/A
Robert Weinmann, MD (LEDGE)	None	N/A	N/A	N/A
Jennifer Yang, MD	None	N/A	N/A	N/A
Selim Yilmaz (LEDGE)	None	N/A	N/A	N/A
Scott Zamvil, MD, PhD	Advisor	Novartis	Yes	*Peer review
	Consultant	Sixsense		
	Speaker	Amgen	No	N/A

*Presentation materials have been peer reviewed and found to be fair, balanced, evidence-based, and free from commercial bias.